Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.54 |
| ▸ | NQO1 | P15559 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | TOP2A | P11388 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194382 | 1.00 | CSNK2A2 (0.54) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL3148984 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL11277491 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL29527683 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL3418071 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL3418628 | 0.92 | THRB (0.45) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL11522777 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL30513721 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| SCHEMBL1202596 | 0.92 | CYP19A1 (0.62) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 | |
| Hydrochloric Acid SCHEMBL11129891 | 0.90 | CYP19A1 (0.60) | CSNK2A2CSNK2BCSNK2A1CSNK2A3NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276537-B2 | Formulations of anthraquinone derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070161808-A1 | Process for the preparation of aq4n | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070027136-A1 | Formulations of anthraquinone derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| EP-1732881-A2 | PROCESS FOR THE PREPARATION OF AQ4N | Kudos Pharmaceuticals Limited (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060205820-A1 | Formulations of anthraquinone derivatives | BTG INTERNATIONAL LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| US-7074835-B2 | Formulations of anthraquinone derivatives | BTG INTERNATIONAL LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| EP-1663147-A1 | FORMULATIONS OF ANTHRAQUINONE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050256188-A1 | Formulations of anthraquinone derivatives | BTG INTERNATIONAL LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| WO-2005080314-A2 | PROCESS FOR THE PREPARATION OF AQ4N | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005025537-A1 | FORMULATIONS OF ANTHRAQUINONE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| EP-1485349-A1 | FORMULATIONS OF ANTHRAQUINONE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003078387-A1 | FORMULATIONS OF ANTHRAQUINONE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027136-A1 | Formulations of anthraquinone derivatives | NQO2, ANTXR2, QTRT2 | CSNK2A2 3560/4885CSNK2B 3349/4885CSNK2A1 3479/4885 |
| US-20050256188-A1 | Formulations of anthraquinone derivatives | ADCY10, GNAQ, PRKAR2A | CSNK2A2 816/4885CSNK2B 709/4885CSNK2A1 765/4885 |
| US-20070161808-A1 | Process for the preparation of aq4n | AQP1, AQP4, AQP3 | CSNK2A2 2576/4885CSNK2B 2709/4885CSNK2A1 2847/4885 |
| US-20060205820-A1 | Formulations of anthraquinone derivatives | ADCY10, GNAQ, PRKAR2A | CSNK2A2 816/4885CSNK2B 709/4885CSNK2A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.